Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

5.790 +0.150 (+2.66%)
Streaming Delayed Price Updated: 10:42 AM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Terns Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates. 
Via Benzinga
Terns (TERN) Q2 Net Loss Narrows 16%
Via The Motley Fool
Topics Intellectual Property
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Top 2 Health Care Stocks That May Collapse This Quarter
 
Via Benzinga
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Via The Motley Fool
Top 3 Health Care Stocks You'll Regret Missing In Q4
 
Via Benzinga
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns has a modest market cap of less than $800 million, and its possible upside could be massive. 
Via The Motley Fool
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Terns Pharmaceuticals just proved that it's competitive in the weight loss field. 
Via The Motley Fool
Should You Invest in This Under-the-Radar Weight Loss Stock?
Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling. 
Via The Motley Fool
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More
This biotech's data suggests that it could have an advantage in its target market. 
Via The Motley Fool
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month
Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and overweight adults, with up to 4.9% placebo-adjusted mean weight loss at the... 
Via Benzinga
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024
TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
3 Biotech Stocks That Could Have Investors Grinning Soon
Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential. 
Via InvestorPlace
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
At least one of the pair has a credible shot at finding a home in the market. 
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024
TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.